Obermatt
See Similar Stocks →

Flags

Financial distress

NeuroPace

NMQ:NPCE · US6412881053
Health Care Equipment & SuppliesSmall

360

30
Profit price85
Owner Earnings Yield1
Dividend Yield1
Price/Sales29
EV / Gross Profit23
Price/Book97
Return on Capital27
Cash Return on Capital8
Return on Equity9
EBIT Margin26
Gross Profitability92
Accruals79
Owner Earnings Margin37
Sales growth17
Profit growth43
Reinvestment93
Price momentum72
Debt load9
Refinancing38
Debt Payback1
Liquidity45
Analyst ratings78
Opinion Changes92
Price Target Upside35
Market mood57
Value Creation6/20not creating value
  • Creates more value than its capital costs
  • Owner earnings growing
  • Owner earnings per share growing
  • Reinvests at strong returns
  • Solid earnings base

What this means

NeuroPace doesn't consistently earn more than its cost of capital, so it isn't yet creating shareholder value.

Profile

CountryUSA
IndustryHealth Care Equipment & Supplies
SizeSmall
TypePublic Company
ExchangeNASDAQGM
Founded1997
Employees217
Websiteneuropace.com
ISINUS6412881053
Last UpdateApr 2, 2026
Indices
NASDAQ (USA)
Themes
Health DiagnosticsNeurologyBiomedical EngineeringCentral Nervous SystemNeuroscienceBiotechnologyHealth Care

Description

NeuroPace, Inc., a medical device company, focuses on transforming the lives of people living with epilepsy by reducing or eliminating the occurrence of debilitating seizures. The company’s novel and differentiated RNS System is the first and only c…

Analysis

Middle-of-the-road

NeuroPace, Inc. is a middle-of-the-road business: neither the economics nor the price stand out from the peer group.

Valuation data is not available for this company.

The trajectory is moderate and the balance sheet is stretched. The company scores 6/20 on our value-creation score: not creating value. Analysts lean positive.

Nothing is flagged here: no red or amber gates, no divergence between profits and cash. That is itself information: the numbers are straightforward. As always: this describes the company's numbers; it is not a recommendation.

360° rank · history

1007550250
76
2023202420252026

All-time high

87

Mar 2026

All-time low

39

Jan 2025

Average rank

63

across all years

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023
Price/Sales
29
42
48
60
Price/Earnings
95
12
12
44
Price/Book
97
1
12
86
Dividend Yield
1
1
1
1
Value (overall)
84
23
32
73

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare NeuroPace with its peers
Ceribell
NSQ:CBLL
37
CountryUSA
IndustryHealth Care Equipment & Supplies
SizeSmall
Full Stock Analysis →
Inspire Medical Systems
NYQ:INSP
66
CountryUSA
IndustryHealth Care Equipment & Supplies
SizeMedium
Full Stock Analysis →
KORU Medical Systems
NAQ:KRMD
40
CountryUSA
IndustryHealth Care Equipment & Supplies
SizeSmall
Full Stock Analysis →
Masimo
NSQ:MASI
44
CountryUSA
IndustryHealth Care Equipment & Supplies
SizeLarge
Full Stock Analysis →
PROCEPT BioRobotics
NMQ:PRCT
19
CountryUSA
IndustryHealth Care Equipment & Supplies
SizeMedium
Full Stock Analysis →
IRadimed
NMQ:IRMD
64
CountryUSA
IndustryHealth Care Equipment & Supplies
SizeSmall
Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100
Learn More →